Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA clears Avantis' Third Eye Retroscope for detection of colon polyps

This article was originally published in Clinica

Executive Summary

Avantis Medical Systems' Third Eye Retroscope has received US FDA 510(k) clearance to detect cancerous and precancerous polyps in the colon. Third Eye is used with colonoscopy to give a backward view of the colon, as well as the standard forward view. This "rear view mirror" can detect polyps in blind spots in the colon that might otherwise be missed. Although colonoscopy is regarded as the gold standard, it can miss 12-24% of polyps and a significant number of cancers, studies have shown. Sunnyvale, California-based Avantis said that Third Eye detected 13% more polyps and 10.9% more adenomas than colonoscopy alone in one study.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043465

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel